Melanoma subsequent to natalizumab exposure: A report from the RADAR (Research on Adverse Drug events And Reports) program-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Melanoma subsequent to natalizumab exposure: A report from the RADAR (Research on Adverse Drug events And Reports) program

Published:2019-03 Issue:3 Volume:80 Page:820-821
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Kelm Ryan C.,Hagstrom Erika L.,Mathieu Regine J.,Orrell Kelsey A.,Serrano Linda,Mueller Kelly A.,Laumann Anne E.,West Dennis P.,Nardone Beatrice

Funder

National Center for Advancing Translational Sciences

Publisher

Elsevier BV

Subject

Dermatology

Reference5 articles.

1. Tysabri prescribing information v. 08/2017.

2. Melanoma complicating treatment with natalizumab for multiple sclerosis: a report from the Southern Network on Adverse Reactions (SONAR);Sabol;Cancer Med,2017

3. Melanoma complicating treatment with natalizumab for multiple sclerosis;Mullen;N Engl J Med,2008

4. Results from the first decade of research conducted by the Research on Adverse Drug events And Reports (RADAR) project;McKoy;Drug Saf,2013

5. Data mining of the public version of the FDA Adverse Event Reporting System;Sakaeda;Int J Med Sci,2013

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dermatological Neoplastic Diseases Complicating Treatment with Monoclonal Antibodies for Multiple Sclerosis;Journal of Clinical Medicine;2024-08-29

2. Evaluation of anticancer therapy-related dermatologic adverse events: Insights from Food and Drug Administration's Adverse Event Reporting System dataset;Journal of the American Academy of Dermatology;2024-07

3. Skin Cancer in the Immunocompromised Patient;Rook's Textbook of Dermatology;2024-03-19

4. Melanoma Risk with Immunomodulators;Melanoma;2024

5. Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis;Frontiers in Cell and Developmental Biology;2023-04-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3